First-quarter sales of the oral Wegovy pill hit $353 million, more than double analyst expectations, as the company lifted ...
Novo Nordisk raised its outlook for 2026 after a strong performance from its newly launched Wegovy pill.
3don MSN
Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the ...
The FDA has proposed removing tirzepatide and semaglutide from its 503B bulk compounding list, a change that would bar outsourcing facilities from producing copies even during future shortages. The ...
Novo Nordisk's 50% Wegovy price cut, aims to secure market share and expand the addressable market. Find out why NVO stock is ...
May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump ...
Ozempic is now available in pill form for people with type 2 diabetes. Novo Nordisk says the oral GLP-1's new lower-dose ...
KELOWNA, BC / / May 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in ...
Amid disruption to the outsourced fill/finish market, PCI is investing $100 million to more than double the capacity to fill ...
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported ...
Beneath Eli Lilly's (LLY) headline numbers lies a structural business model shift that the broader market seems to currently undervalue, driven in part by a recent valuation penalty following Novo ...
Disney (NYSE:DIS): beat on earnings and revenue driven by strong streaming and theme park performance; shares jumped 7.5% o Uber (NYSE:UBER): revenue slightly missed expectations but bookings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results